Clinical efficacy of neoadjuvant chemotherapy combined with radical gastrectomy in elderly patients with advanced gastric cancer

Table 1 Comparison of baseline data between two groups of gastric cancer patients (cases)

Clinical indicators	Number of cases	Middle aged and young group (n = 111)	Elderly group (n = 37)	χ2 value	P value
Gender				0.062	0.803
Female	26	20	6	-	-
Male	122	91	31	0.885	0.347
Underlying disease
No	105	81	24	-	-
Yes	43	30	13	-	-
BMI (kg/m2), mean ± SD	-	22.9 ± 4.3	21.9 ± 2.7	1.369	0.245
Tumor site				0.997	0.607
Upper part of stomach	94	69	25
Middle part of stomach	19	16	3
Lower part of stomach	35	26	9
Clinical stages				0.022	0.882
Phase II	17	13	4
Phase III	131	98	33
Neoadjuvant chemotherapy regimen				4.214	0.239
FOLFOX	81	66	15
SOX	55	37	18
XELOX	7	5	2
FLOT	5	3	2
Neoadjuvant chemotherapy cycle				0.225	0.635
< 3	73	56	17
≥ 3	75	55	20
Operation				0.580	0.446
Laparoscope	80	58	22
Openness	68	53	15
Postoperative chemotherapy				0.379	0.538
No	46	33	13
Yes	102	78	24

BMI: Body mass index; FOLFOX: Fluorouracil, leucovorin, and oxaliplatin; SOX: Sex-determining region Y-box; XELOX: Capecitabine and oxaliplatin; FLOT: Fluorouracil, leucovorin, oxaliplatin, taxotere.